SCHEMBL28512

SCHEMBL28512

N[C@@H](Cc1ccc(O)c(Cl)c1)C(=O)O

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 4/20 0.73
USP2 O75604 3/20 0.73
PTGS1 P23219 2/20 0.73
KDM4E B2RXH2 2/20 0.73
ALOX15 P16050 2/20 0.73
RECQL P46063 2/20 0.73
HIF1A Q16665 2/20 0.73
HSD17B10 Q99714 2/20 0.73
TDP1 Q9NUW8 2/20 0.73
EGFR P00533 1/20 0.73
LCK P06239 1/20 0.73
FYN P06241 1/20 0.73
ADORA3 P0DMS8 1/20 0.73
HTR2A P28223 1/20 0.73
PTGS2 P35354 1/20 0.73
CA2 P00918 3/20 0.57
PKM P14618 3/20 0.53
ALPI P09923 1/20 0.53
XIAP P98170 1/20 0.53
GRIA2 P42262 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL157442 1.00 SLC7A5 (0.73) SLC7A5USP2PTGS1KDM4EALOX15
SCHEMBL29778 1.00 SLC7A5 (0.73) SLC7A5USP2PTGS1KDM4EALOX15
SCHEMBL29405778 1.00 SLC7A5 (0.73) SLC7A5USP2PTGS1KDM4EALOX15
Hydrochloric Acid SCHEMBL7042725 0.98 SLC7A5 (0.71) SLC7A5USP2PTGS1KDM4EALOX15
Hydrochloric Acid SCHEMBL7042729 0.98 SLC7A5 (0.71) SLC7A5USP2PTGS1KDM4EALOX15
SCHEMBL9506322 0.91 SLC7A5 (0.61) SLC7A5USP2PTGS1KDM4EALOX15
SCHEMBL25578547 0.87 ALOX15 (0.54) SLC7A5USP2PTGS1KDM4EALOX15
SCHEMBL29478421 0.86 SLC7A5 (0.62) SLC7A5USP2PTGS1KDM4EALOX15
SCHEMBL43915 0.86 SLC7A5 (0.62) SLC7A5USP2PTGS1KDM4EALOX15
Levodopa SCHEMBL29868926 0.86 SLC7A5 (0.96) SLC7A5USP2PTGS1KDM4EALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1823 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3869192-B1 METHOD FOR QUANTITATIVE DETECTION OF VARIOUS METABOLITES IN BIOLOGICAL SAMPLE HUMAN METABOLOMICS INST INC (CN) 2026-05-13 EP claimed
US-12600699-B2 Thiosemicarbazates and uses thereof THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) 2026-04-14 US claimed
US-20250258146-A1 QUANTITATIVE DETECTION METHOD OF MULTIPLE METABOLITES IN BIOLOGICAL SAMPLE AND METABOLIC CHIP HUMAN METABOLOMICS INSTITUTE INC. (CN) 2025-08-14 US claimed
US-12351573-B2 Compounds for use in synthesis of peptidomimetics THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) 2025-07-08 US claimed
CN-119424050-A Degradable valve frame and heart valve 元心科技(深圳)有限公司 2025-02-14 CN claimed
WO-2025026273-A1 DEGRADABLE VALVE STENT, VALVE STENT FOR PULMONARY ARTERIAL VALVE, PULMONARY ARTERIAL VALVE, AND HEART VALVE 元心科技(深圳)有限公司 2025-02-06 WO claimed
US-20240336654-A1 ANTIMICROBIAL PEPTIDOMIMETICS Universität Zürich (CH) 2024-10-10 US claimed
CN-118688315-A Multichannel high-coverage synchronous quantification method for amino-containing and hydroxyl-containing compounds 复旦大学 2024-09-24 CN claimed
EP-3655036-B1 COMPOSITIONS FOR TREATING STRESS-RELATED DISORDERS HOFFMAN TECH LLC (US) 2024-09-04 EP claimed
US-20240269228-A1 SELECTIVE PENICILLAMINE SUBSTITUTION ENABLES DEVELOPMENT OF A POTENT ANALGESIC PEPTIDE THAT ACTS THROUGH A NON-OPIOID BASED MECHANISM UNIVERSITY OF UTAH RESEARCH FOUNDATION 2024-08-15 US claimed
EP-0931264-B1 DIAGNOSTIC METHOD FOR ATHEROSCLEROSIS UNIV WASHINGTON (US) 2002-04-17 EP claimed
US-20020035104-A1 Integrin receptor inhibitors GENENTECH, INC. 2002-03-21 US claimed
WO-2002016313-A2 INTEGRIN RECEPTOR INHIBITORS GENENTECH, INC. (US) 2002-02-28 WO claimed
US-6268220-B1 Diagnostic method for atherosclerosis WASHINGTON UNIVERSITY 2001-07-31 US claimed
EP-0931264-A1 DIAGNOSTIC METHOD FOR ATHEROSCLEROSIS WASHINGTON UNIVERSITY (US) 1999-07-28 EP claimed
WO-1998010294-A1 DIAGNOSTIC METHOD FOR ATHEROSCLEROSIS WASHINGTON UNIVERSITY (US) 1998-03-12 WO claimed
EP-0484437-A4 RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION SEARLE & CO (US) 1994-06-01 EP claimed
EP-0484437-A1 RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION G.D. Searle & Co. (US) 1992-05-13 EP claimed
WO-1992001667-A1 RENAL-SELECTIVE PRODRUGS FOR CONTROL OF RENAL SYMPATHETIC NERVE ACTIVITY IN THE TREATMENT OF HYPERTENSION G.D. SEARLE & CO. (US) 1992-02-06 WO claimed
WO-1991001724-A1 RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION G.D. SEARLE & CO. (US) 1991-02-21 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12351573-B2 Compounds for use in synthesis of peptidomimetics DNPEP, NPEPPS, PAM SLC7A5 1166/4885USP2 2161/4885PTGS1 2925/4885
US-20020035104-A1 Integrin receptor inhibitors ITGB1, ITGA1, ITGA4 SLC7A5 4309/4885USP2 4817/4885PTGS1 2112/4885
US-12600699-B2 Thiosemicarbazates and uses thereof MET, THRB, ABAT SLC7A5 64/4885USP2 1460/4885PTGS1 3489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.